Immunocore Holdings plc Operating Lease Cost
Immunocore Holdings plc (IMCR) reported Operating Lease Cost of $5.34 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-25
- Immunocore Holdings plc operating lease, cost for fiscal 2025 was $5.34M, a 19.49% increase from fiscal 2024.
- Immunocore Holdings plc operating lease, cost for fiscal 2024 was $4.47M, a 5.95% increase from fiscal 2023.
- Immunocore Holdings plc operating lease, cost for fiscal 2023 was $4.22M, a 12.51% increase from fiscal 2022.
- Immunocore Holdings plc operating lease, cost for fiscal 2022 was $3.75M, a 4.14% decline from fiscal 2021.
| Period end | Operating Lease, Cost 12 month |
|---|---|
| 2025-12-31 | $5.34M 10-K · filed 2026-02-25 |
| 2024-12-31 | $4.47M 10-K · filed 2026-02-25 |
| 2023-12-31 | $4.22M 10-K · filed 2026-02-25 |
| 2022-12-31 | $3.75M 10-K · filed 2025-02-26 |
| 2021-12-31 | $3.91M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |